Morgenthaler's Life Science Team focuses on medical devices and therapeutic pharmaceuticals. Recent investments include Avidia, Morphotek, Threshold Pharmaceuticals, Replidyne, Orexigen, Thermage, Emphasys, Satiety, Cierra, Ardian, Cabochon Aesthetics, Transcend and Xtent. The firm has approximately $2.5 billion under management and has funded more than 250 companies since 1968. For more information on Morgenthaler portfolio companies and the firm, please visit: http://www.morgenthaler.com/ventures.
About Split Rock Partners
Split Rock Partners, with offices in Menlo Park and Minneapolis, invests in emerging opportunities in healthcare and internet services primarily on the West Coast and the Upper Midwest. Split Rock Partners was formed in June, 2004 by the healthcare and software investment teams of St. Paul Venture Capital. In April, 2005, Split Rock announced the closing of a new $275 million venture fund. Split Rock Partners' portfolio of healthcare investments has included such industry leading companies as SpineTech, The Foundry, Dexcom, Emphasys Medical, Xtent, Atritech, Prometheus Labs, and many others. Additional information about the firm can be found at http://www.splitrock.com .
About Versant Ventures
Founded in 1999, Versant Ventures is a leading healthcare venture
capital firm that currently manages over $1 billion in committed capital.
Since its formation, Versant has invested in more than 75 companies in the
Medical Device, Biotech, Healthcare Services and Healthcare Information
Technology sectors. The Versant team of twelve investment professionals
located in Menlo Park and Newport Beach bring together more than 175 years
of combined experience and success as venture capitalists and
entrepreneurs. Versant invests in early-stage healthcare companies
promising to be significant,
|SOURCE ForSight Labs LLC|
Copyright©2007 PR Newswire.
All rights reserved